What are psychedelic substances? Why are they currently being researched in the medical field? Are psychedelics already available for treatment in Europe? These are some of the issues addressed in a new set of EUDA Frequently Asked Questions (FAQs): therapeutic use of psychedelic substances released today.
32077_enThe FAQs are published in response to the growing interest in the therapeutic use of psychedelic substances and the need for reliable information on the topic. The digital resource is based on the findings from an EUDA project to develop a better understanding of key developments in this field and to respond to concerns raised by policymakers and other key customers and stakeholders.
An increasing number of clinical studies are exploring the potential of a range of psychedelic substances for different mental health conditions. These developments have received considerable media attention, raising concerns that this may encourage greater experimental use of a range of potent psychoactive substances. At the same time, there are also signs of unregulated programmes being operated in the European Union and elsewhere, in which the use of psychedelic substances is included as part of a wellness, therapeutic or spiritually oriented intervention. The information available also suggests that in some countries, subgroups or settings, the use of some psychedelics has become more common. Strengthening monitoring in this area will as such be important in the future.
In recent years, a number of jurisdictions outside the EU have also begun regulating the use of psychedelics for medical and therapeutic purposes. Significant commercial interest has arisen in this area, evidenced through the appearance of so-called ‘psychedelic retreats’ in a number of countries.
The FAQs cover a wide range of topics, including the definition and classification of psychedelic substances, their current legal status, patterns of use in Europe and ongoing clinical research. Additionally, the FAQs address the potential risks and benefits of these substances as shown by clinical studies, providing a balanced perspective based on the available research.
